JP6666264B2 - 新規安定型抗体薬物複合体の作製およびその応用 - Google Patents

新規安定型抗体薬物複合体の作製およびその応用 Download PDF

Info

Publication number
JP6666264B2
JP6666264B2 JP2016563404A JP2016563404A JP6666264B2 JP 6666264 B2 JP6666264 B2 JP 6666264B2 JP 2016563404 A JP2016563404 A JP 2016563404A JP 2016563404 A JP2016563404 A JP 2016563404A JP 6666264 B2 JP6666264 B2 JP 6666264B2
Authority
JP
Japan
Prior art keywords
linker
group
integer
ring
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016563404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514812A5 (https=
JP2017514812A (ja
Inventor
ガン チン
ガン チン
ジンドゥオ ユアン
ジンドゥオ ユアン
ルー ジアン
ルー ジアン
チュービン タン
チュービン タン
リリ シー
リリ シー
ソウ リョ
ソウ リョ
レイレイ チェン
レイレイ チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genequantum Healthcare Suzhou Co Ltd
Original Assignee
Genequantum Healthcare Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genequantum Healthcare Suzhou Co Ltd filed Critical Genequantum Healthcare Suzhou Co Ltd
Publication of JP2017514812A publication Critical patent/JP2017514812A/ja
Publication of JP2017514812A5 publication Critical patent/JP2017514812A5/ja
Application granted granted Critical
Publication of JP6666264B2 publication Critical patent/JP6666264B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016563404A 2014-04-29 2015-04-29 新規安定型抗体薬物複合体の作製およびその応用 Active JP6666264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410174890.8 2014-04-29
CN201410174890 2014-04-29
PCT/CN2015/077887 WO2015165413A1 (zh) 2014-04-29 2015-04-29 一种新型的稳定型抗体药物耦联物及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019215918A Division JP7100617B2 (ja) 2014-04-29 2019-11-29 新規安定型抗体薬物複合体の作製およびその応用

Publications (3)

Publication Number Publication Date
JP2017514812A JP2017514812A (ja) 2017-06-08
JP2017514812A5 JP2017514812A5 (https=) 2017-07-20
JP6666264B2 true JP6666264B2 (ja) 2020-03-13

Family

ID=54358190

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016563404A Active JP6666264B2 (ja) 2014-04-29 2015-04-29 新規安定型抗体薬物複合体の作製およびその応用
JP2019215918A Active JP7100617B2 (ja) 2014-04-29 2019-11-29 新規安定型抗体薬物複合体の作製およびその応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019215918A Active JP7100617B2 (ja) 2014-04-29 2019-11-29 新規安定型抗体薬物複合体の作製およびその応用

Country Status (8)

Country Link
US (5) US11040084B2 (https=)
EP (2) EP3138568B1 (https=)
JP (2) JP6666264B2 (https=)
KR (1) KR102511249B1 (https=)
CN (2) CN106856656B (https=)
AU (2) AU2015252518B2 (https=)
ES (1) ES2736505T3 (https=)
WO (1) WO2015165413A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6666264B2 (ja) 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN115175917A (zh) * 2019-12-31 2022-10-11 启德医药科技（苏州）有限公司 药物缀合物及其应用
US20230101266A1 (en) * 2019-12-31 2023-03-30 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
US20230399616A1 (en) * 2020-10-30 2023-12-14 Westlake Therapeutics (Hangzhou) Co. Limited Modified Red Blood Cells and Uses Thereof for Delivering Agents
CN115867283A (zh) * 2020-12-23 2023-03-28 启德医药科技（苏州）有限公司 包含开环硫代琥珀酰亚胺基团、寡肽片段和手性部分的新型异构化合物
KR20230147105A (ko) 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
AU2022232674B2 (en) * 2021-03-08 2025-08-28 Brightgene Bio-Medical Technology Co., Ltd. Anti-her2 antibody-immune agonist conjugate and applications thereof
KR102917231B1 (ko) 2021-03-08 2026-01-26 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체 면역 작용제 접합체 및 이의 적용
CN117177775A (zh) * 2021-04-14 2023-12-05 启德医药科技（苏州）有限公司 连接子、缀合物及其应用
TW202308700A (zh) * 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
WO2023104134A1 (en) * 2021-12-09 2023-06-15 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody-cytokine fusion proteins and applications thereof
WO2023185907A1 (en) * 2022-03-29 2023-10-05 Genequantum Healthcare (Suzhou) Co., Ltd. A freeze-drying process for an ADC
EP4534090A1 (en) 2022-06-02 2025-04-09 Genequantum Healthcare (Suzhou) Co., Ltd. Oligosaccharide linker, linker-supported material comprising oligosaccharide linker, antibody-drug conjugate having sugar chain remodeling, preparation method therefor and use thereof
CN119630427A (zh) * 2022-06-28 2025-03-14 启德医药科技（苏州）有限公司 抗fgfr3抗体缀合物及其医疗用途
AU2023296781A1 (en) 2022-07-01 2025-02-13 Genequantum Healthcare (Suzhou) Co., Ltd. Immobilized endoglycosidase fusion protein and use thereof
AU2023305694A1 (en) * 2022-07-15 2025-02-20 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
IL318296A (en) 2022-07-15 2025-03-01 Genequantum Healthcare Suzhou Co Ltd Anti-TROP2 antibody and its conjugate
AU2023328010A1 (en) 2022-08-25 2025-03-20 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition of antibody drug conjugate
WO2024078612A1 (en) * 2022-10-14 2024-04-18 Genequantum Healthcare (Suzhou) Co., Ltd. Linker-payload compound, conjugates and applications thereof
CN120957726A (zh) * 2023-03-21 2025-11-14 启德医药科技（苏州）有限公司 抗体-药物偶联物与癌症疗法的组合及其用途
WO2024199432A1 (en) * 2023-03-30 2024-10-03 Genequantum Healthcare (Suzhou) Co., Ltd. Site-speicfic orthogonal bioconjugate modality and application thereof
KR20260027874A (ko) 2023-04-13 2026-03-03 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체-약물 접합체와 항-pd-1 항체의 조합물 및 이의 용도
WO2025149014A1 (en) 2024-01-12 2025-07-17 Genequantum Healthcare (Suzhou) Co., Ltd. Pharmaceutical composition
WO2025255054A1 (en) * 2024-06-03 2025-12-11 Darbix Llc Methods and compositions for oligonucleotide bioconjugation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7241020B2 (en) * 2003-11-20 2007-07-10 Mirror Lite High definition vehicular mirror
NZ579482A (en) * 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
SG189817A1 (en) * 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
RU2661083C2 (ru) * 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
CN105722851A (zh) * 2013-04-28 2016-06-29 秦刚 一种新型的连接子及其制备方法和用途
JP6666264B2 (ja) 2014-04-29 2020-03-13 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー．Ｇｅｎｅｑｕａｎｔｕｍ Ｈｅａｌｔｈｃａｒｅ （Ｓｕｚｈｏｕ）Ｃｏ．， Ｌｔｄ． 新規安定型抗体薬物複合体の作製およびその応用
CN107828351B (zh) 2016-09-15 2021-07-27 E·I·内穆尔杜邦公司 用于粘合的导电糊料
EP3821005A4 (en) 2018-07-09 2022-10-26 Genequantum Healthcare (Suzhou) Co., Ltd. AGAINST TROPHOBLAST ANTIGEN 2 (TROP2) SPECIFIC ANTIBODIES
US20230101266A1 (en) 2019-12-31 2023-03-30 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-trop2 antibodies, antibody-drug conjugates, and application of the same
KR20230147105A (ko) 2021-01-28 2023-10-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 리가제 융합 단백질 및 그 응용
KR102942648B1 (ko) 2021-02-09 2026-03-20 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 결합 장치 및 결합 화합물을 생성하는 방법
KR102917231B1 (ko) 2021-03-08 2026-01-26 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체 면역 작용제 접합체 및 이의 적용
CN117177775A (zh) 2021-04-14 2023-12-05 启德医药科技（苏州）有限公司 连接子、缀合物及其应用

Also Published As

Publication number Publication date
JP7100617B2 (ja) 2022-07-13
US20170112944A1 (en) 2017-04-27
US20210177929A1 (en) 2021-06-17
KR102511249B1 (ko) 2023-03-20
WO2015165413A1 (zh) 2015-11-05
US20210401924A1 (en) 2021-12-30
WO2015165413A8 (zh) 2016-04-14
CN106856656B (zh) 2021-01-26
CN112999362B (zh) 2023-11-14
US20240156894A1 (en) 2024-05-16
AU2015252518B2 (en) 2019-11-14
CN112999362A (zh) 2021-06-22
JP2020055828A (ja) 2020-04-09
CN106856656A (zh) 2017-06-16
AU2015252518A1 (en) 2016-12-15
AU2020200975A1 (en) 2020-02-27
JP2017514812A (ja) 2017-06-08
KR20170020328A (ko) 2017-02-22
US11911434B2 (en) 2024-02-27
US11911435B2 (en) 2024-02-27
EP3517114A1 (en) 2019-07-31
US11040084B2 (en) 2021-06-22
AU2020200975B2 (en) 2021-01-28
EP3138568A4 (en) 2017-12-13
ES2736505T3 (es) 2020-01-02
US20240165192A1 (en) 2024-05-23
AU2015252518A2 (en) 2016-12-15
EP3138568B1 (en) 2019-04-17
EP3138568A1 (en) 2017-03-08

Similar Documents

Publication Publication Date Title
JP6666264B2 (ja) 新規安定型抗体薬物複合体の作製およびその応用
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
EP3783025A1 (en) Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
EP3380495B1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
WO2016074093A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
JP6876618B2 (ja) 治療目的のための抗体−ウレアーゼコンジュゲート
CN104781281A (zh) 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物
CN116761824B (zh) 工程化抗-trop2抗体及其抗体-药物偶联物
AU2021274149B2 (en) Novel nucleolin-binding peptide and use thereof
WO2025206033A1 (ja) ｕＰＡＲ結合性ＨＬＨペプチド、ペプチド－薬物複合体および組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190731

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200220

R150 Certificate of patent or registration of utility model

Ref document number: 6666264

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250